Cargando…
Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte–Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study
Purpose: The aim of the study was to evaluate the cost-effectiveness of PEGylated recombinant human granulocyte–stimulating factor (PEG-rhG-CSF) as a means of achieving primary and secondary prophylaxis against chemotherapy-induced neutropenia cancer cases. Methods: Individuals who underwent PEG-rhG...
Autores principales: | Wu, Qiuji, Li, Qiu, Zhang, Jun, Luo, Zhumei, Zhou, Jin, Chen, Jing, Luo, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586644/ https://www.ncbi.nlm.nih.gov/pubmed/34776940 http://dx.doi.org/10.3389/fphar.2021.690874 |
Ejemplares similares
-
Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor
por: Zhao, Tong, et al.
Publicado: (2023) -
Pegylated recombinant human granulocyte colony‐stimulating factor regulates the immune status of patients with small cell lung cancer
por: Sun, Jing, et al.
Publicado: (2020) -
Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony‐stimulating factor as support to chemotherapy for lung cancer
por: Ji, Xiang, et al.
Publicado: (2021) -
Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity
por: Kumari, Monika, et al.
Publicado: (2020) -
Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children
por: Thakkar, Dhwanee, et al.
Publicado: (2021)